Certara, Inc. (CERT) stock analysis

Healthcare · Health Information Services

From the 10-K filed 2026-02-26

How it makes money

It earns revenue by selling proprietary biosimulation software licenses and expert consulting services to global biopharmaceutical and biotech companies.

Biopharmaceutical and biotech companies pay for software and consulting services to implement Model-Informed Drug Development, known as MIDD. This approach uses computer-aided mathematical simulation of biological processes to predict how a drug behaves in humans, which helps companies make better decisions during research and development.

Profitability is primarily driven by the adoption of these simulation tools and expert services by life sciences companies seeking to increase the probability of regulatory success and reduce development costs.

What protects it: the moat

It protects its market position through proprietary biosimulation platforms, two decades of validation data, and specialized regulatory expertise.

The company builds its software on biology, chemistry, and pharmacology principles combined with algorithms developed over more than two decades. It also leverages its expertise in incorporating data into regulatory documents to streamline filings.

Competitors include other scientific software providers, internal development teams at biopharmaceutical companies, academic institutions, and open source solutions, making the market competitive and fragmented according to management's claims.

What growth costs

The filing does not disclose the specific ongoing reinvestment figures required for maintaining and growing its earnings.

While the business relies on ongoing scientific development, data standardization, and the integration of artificial intelligence and machine learning technologies across its portfolios, the provided text does not specify the exact financial amounts spent on these reinvestments.

What could damage it

A widespread academic or regulatory shift away from computer-based simulation data could reduce demand for its products and impair earnings.

If regulatory authorities or academic institutions reverse their level of adoption and reliance upon computer simulation data in the drug approval process, demand for its software and services would decline. This reduction in adoption could directly harm its business, financial condition, and results of operations.

About Certara, Inc.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Other companies in Health Information Services